Biofil Chemicals Reports Strong Q1 FY27 Results; Plans Manufacturing Upgradation
Biofil Chemicals & Pharmaceuticals Limited has announced the Un-Audited Financial Results for the quarter ended June 30, 2026. The Board of Directors reviewed and approved these results alongside a limited Review Report from the statutory auditors.The company reported robust performance in the first quarter of the financial year, with its net sales/income from operations reaching 1,235.02 Lakhs for the period.
Financial Highlights and Segment Performance
The quarterly results were reviewed by the Audit Committee and approved by the Board, adhering to Indian Accounting Standard (Ind AS). The company reported two business segments: Pharma Division and Chemical Division.Key financial figures for the quarter ended June 30, 2026, compared to the corresponding previous period, are summarized in the table below (amounts are in Lakhs):
| Particulars | June 30, 2026 (Un-Audited) | June 30, 2025 (Un-Audited) | March 31, 2026 (Audited) |
|---|---|---|---|
| Revenue from Operations | 1,235.02 | 643.26 | 756.56 |
| Total Income | 6.26 | 283.20 | 10.85 |
| Profit Before Tax | 13.41 | 276.25 | 344.96 |
Segment-wise performance is detailed as follows:
| Segment | Revenue from Operations (June 30, 2026) | Profit Before Tax |
|---|---|---|
| Chemical Division | 921.62 Lakhs | 15.43 Lakhs |
| Pharma Division | 313.40 Lakhs | (6.41) Lakhs |
Operational and Governance Updates
The company management attributed the increase in revenue from operations for the quarter ended June 30, 2026, relative to the prior year's corresponding period to an increase in trading activities, resulting in higher sales of traded goods.Looking ahead, Biofil Chemicals & Pharmaceuticals Limited is currently undertaking renovation and upgradation of its manufacturing facility as part of revisions in Schedule M of the Drugs and Cosmetics Rules. This upgradation work is expected to be completed within approximately 3 to 6 months, with management anticipating that enhanced capabilities will support improved sales in subsequent periods.
During the Board meeting held on August 11, 2026, the company also approved several governance matters. These included the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director upon attaining the age of seventy-five years, and the approval of the Corporate Governance Report and Management Discussion and Analysis Report for the year ended March 31, 2026.
The Board also convened an Annual General Meeting (AGM) scheduled for Wednesday, September 23, 2026, which will be conducted through Video Conferencing or other Audio-Visual Means.
BIOFILCHEM Stock Price Movement
Biofil Chemicals & Pharmaceuticals Limited shares gained 0.49% on Tuesday, edging higher in the market and settling at ₹32.80 after closing the trading session. The stock saw total traded volume of 9,737 shares for the day, operating within a daily range bounded by ₹32.2 to ₹34.0.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.